---
figid: PMC9323819__curroncol-29-00399-g006
pmcid: PMC9323819
image_filename: curroncol-29-00399-g006.jpg
figure_link: /pmc/articles/PMC9323819/figure/curroncol-29-00399-f006/
number: Figure 6
figure_title: ''
caption: 'Different therapeutic options and targets in PBL, Modified from Pileri SA,
  Mazzara S, and Derenzini E []. Abbreviations: (HDAC: histone deacetylase, BRAF:
  B-Raf proto-oncogene, MEK: mitogen-activated protein kinase, ERK: mitogen-activated
  protein kinase, DDR: DNA damage response pathway, BET: bromodomain and extra terminal
  protein, HAART: highly active anti-retroviral therapy).'
article_title: 'Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete
  Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential
  Novel Treatment Approach.'
citation: Waleed Sabry, et al. Curr Oncol. 2022 Jul;29(7):5042-5053.
year: '2022'

doi: 10.3390/curroncol29070399
journal_title: Current Oncology
journal_nlm_ta: Curr Oncol
publisher_name: MDPI

keywords:
- plasmablastic lymphoma (PBL)
- targeted therapy
- bortezomib

---
